Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
January 24, 2020
January 24, 2020
5e0485fc-a570-4965-bae5-05741639f886
Related Documents
Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment: Guidance for Industry
Guidance DocumentJune 28, 2022Office of the Commissioner
Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment: Guidance for Industry
Guidance DocumentJune 27, 2022Office of the Commissioner
Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment: Guidance for Industry; Availability
Guidance DocumentOctober 17, 2022Office of the Commissioner
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.